Making Gene Therapy for Blindness Accessible with Dr. Alex Levin

In this episode of Mission Matters Business Podcast, host Adam Torres interviews Dr. Alex Levin, Chief Pediatric Ophthalmology and Ocular Genetics at the FLOM Eye Institute at the University of Rochester. Levin shares his groundbreaking work in developing low-cost, open-access gene therapies to treat and prevent genetic blindness, particularly in underserved populations. He discusses the transformative potential of gene therapy—such as Luxturna, which restored vision in children born blind—while highlighting the prohibitive $1 million price tag that makes it inaccessible globally. In response, Levin and his team at the University of Iowa have pioneered a philanthropy-driven model that produces the same treatments for just $50 per patient, bypassing pharmaceutical patents and profit motives. The conversation also touches on Levin’s personal journey, his emotional experiences with patients and families, and the urgent need for more funding to scale these treatments worldwide. He emphasizes the paradox of higher disease burden in low-income countries with lower access, and how organizations like Orbis and Cybersight are working to bridge that gap through education and mobile medical missions. Levin’s vision is both hopeful and urgent: to replicate this open-access model across hundreds of rare genetic eye diseases, one gene at a time. He stresses that the science is ready, but the system must shift to prioritize human health over profit. The episode concludes with a call to action for listeners to support this mission through donations, collaboration, or direct contact with Levin’s team. The tone is deeply inspiring, blending scientific triumph with moral urgency, and underscores the power of collective action in transforming healthcare equity.